1. Low expression in lung adenocarcinoma; high expression correlates with increased CD8+T cell and DC infiltration and improved immunotherapy response;2. LNP-encapsulated cEMSY combined with PD-1 inhibitors induces long-term anti-tumor immunity without obvious toxicity. Here, CD8A is linked to lung adenocarcinoma.